#SFHS2612882AFrance Adds Axitinib Accord to Public Healthcare Medicine List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds three Axitinib Accord cancer medicine presentations, in 1 mg, 3 mg, and 5 mg tablets, to the list of medicines approved for use by public healthcare institutions and public services. Reimbursement by health insurance is limited to adult patients with advanced kidney cancer after a prior treatment with sunitinib or cytokine has failed. Prescribing is restricted to hospital doctors, oncology specialists, or doctors qualified in cancer care.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Axitinib Accord 1 mg tablets to the approved public healthcare medicines list
- Adds Axitinib Accord 3 mg tablets to the approved public healthcare medicines list
- Adds Axitinib Accord 5 mg tablets to the approved public healthcare medicines list
Obligations
What this law requires
Public healthcare institutions and public services may use AXITINIB ACCORD 1 mg, 3 mg, and 5 mg film-coated tablets only as listed approved pharmaceutical specialties under the annex to this order.
Health insurance coverage for the listed AXITINIB ACCORD presentations is limited to treatment of adult patients with advanced renal cell carcinoma after failure of prior treatment with sunitinib or cytokine.
Prescriptions of the listed AXITINIB ACCORD presentations for the reimbursed indication must be restricted to hospital doctors, oncology specialists, or doctors qualified in cancer care.